Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Safety and Pharmacokinetic Study of QBI-139 Injection Administered by Weekly Intravenous Infusion in Patients With Refractory Malignancies

NCT00818831 is registered in ClinicalTrials.gov with Quintessence Biosciences, Inc. as lead sponsor.

NCT NCT00818831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00818831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Safety and Pharmacokinetic Study of QBI-139 Injection Administered by Weekly Intravenous Infusion in Patients With Refractory Malignancies
Lead sponsor
Quintessence Biosciences, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
January 31, 2009
Completion date
Not reported
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors